U.S. markets close in 2 hours 4 minutes

Bright Minds Biosciences Inc. (DRUG)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.0100+0.1000 (+10.99%)
As of 01:34PM EDT. Market open.

Bright Minds Biosciences Inc.

1500 – 1055 West Georgia Street
Vancouver, BC V6E 4N7

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Ian McDonaldCo-Founder, CEO, Pres & DirectorN/AN/A1988
Mr. Ryan E. S. K. Cheung B.Com., CA, CPAChief Financial Officer66.85kN/A1978
Dr. Revati Shreeniwas FCCP, M.D., Ph.D.Chief Medical Officer188.47kN/A1961
Dr. Emer Leahy M.B.A., Ph.D.ConsultantN/AN/A1967
Dr. Jan Torleif Pedersen M.Sc., Ph.D.Interim Chief Science Officer & DirectorN/AN/AN/A
Dr. Gideon Shapiro Ph.D.VP of DiscoveryN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Corporate Governance

Bright Minds Biosciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.